✨ Your Portfolio is fetched and updated from zerodha.
Nano Pharmaceuticals

Samrat Pharmachem Ltd.

SAMRATPH

Get real time AI alerts about this company on your WhatsApp!
Market Cap
₹81 Cr.
P/E
51.50

Samrat Pharmachem Ltd.

  • Samrat Pharmachem
  • Bandaram Pharma Pack
  • Amwill Health Care

FAQs on Samrat Pharmachem Ltd. Shareprice

Samrat Pharmachem has given better returns compared to its competitors.
Samrat Pharmachem has grown at ~24.94% over the last 7yrs while peers have grown at a median rate of 18.31%

Samrat Pharmachem is expensive when considering the PE ratio, however latest EV/EBIDTA is < 3 yr avg EV/EBIDTA.
Latest PE of Samrat Pharmachem is 51.57, while 3 year average PE is 18.55.
Also latest EV/EBITDA of Samrat Pharmachem is 20.1 while 3yr average is 26.18.

View FAQ's On Business

Growth Table

  • Samrat Pharmachem Ltd.
  • Bandaram Pharma Pack
  • Amwill Health Care

Balance Sheet

  • Samrat Pharmachem Ltd.
  • Bandaram Pharma Pack
  • Amwill Health Care

Balance Sheet Snapshot

No data available.

Fund Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end

Profit & Loss

  • Samrat Pharmachem Ltd.
  • Bandaram Pharma Pack
  • Amwill Health Care

Cash Flow

  • Samrat Pharmachem Ltd.
  • Bandaram Pharma Pack
  • Amwill Health Care

Cash Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.

Ratios

= Dominant Factor
  • Samrat Pharmachem Ltd.
  • Bandaram Pharma Pack
  • Amwill Health Care

Quarterly Results

  • Samrat Pharmachem Ltd.
  • Bandaram Pharma Pack
  • Amwill Health Care

Reverse DCF

locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*
*Implied Growth calculated using Newton-Raphson method.
Learn how to use Reverse DCF

FAQs on Samrat Pharmachem Ltd. Financials

Balance sheet of Samrat Pharmachem is strong.
It shouldn't have solvency or liquidity issues.

The net debt of Samrat Pharmachem is decreasing.
Latest net debt of Samrat Pharmachem is ₹0.56 Crs as of Sep-25.
This is less than Mar-25 when it was ₹9.63 Crs.

The profit is oscillating.
The profit of Samrat Pharmachem is ₹1.57 Crs for TTM, ₹7.11 Crs for Mar 2025 and ₹2.16 Crs for Mar 2024.

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Samrat Pharmachem latest dividend payout ratio is 4.34% and 3yr average dividend payout ratio is 6.83%

Companies resources are allocated to majorly unproductive assets like Capital Work in Progress, Inventory, Short Term Loans & Advances

View FAQ's On Shareholding
Ideas Dashboard
Results
Timeline
Watchlist
Portfolio
Alerts
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech